GSTM1 and pelvic inflammatory disease: Following PSM, the LNG-IUD group demonstrated a significantly lower risk of PID (HR 0.545; 95% CI 0.483–0.616) and Hb < 10 g/dL (HR 0.850; 95% CI 0.775–0.932) compared with the norethindrone group.